Skip to main content

Laura Puente Ramo

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Laura Puente Ramo

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Projects

Caracterización de las claves fisiopatológicas y fenotipos de la enfermedad del hígado graso metabólica con ingesta moderada de alcohol para identificar nuevas terapias (ReLiveR).

IP: Meritxell Ventura Cots
Collaborators: Immaculada Raurell Saborit, Juan Manuel Pericàs Pulido, Laura Puente Ramo, Ares Aurora Villagrasa Vilella, Juan Bañares Sanchez, Jesus Manuel Rivera Esteban
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI22/01770
Duration: 01/01/2023 - 31/12/2025

Impacto de la cirugía bariátrica en la hemodinámica portal en pacientes con obesidad mórbida y NAFLD. Estudio HEYMDAL.

IP: Ramón Vilallonga Puy
Collaborators: Mercedes Pérez Lafuente, Nuria Roson Gradaille, Laura Puente Ramo, Carla Gonzalez Junyent, Marta Comas Martínez, Alba Rojano Toimil, Arturo Cirera De Tudela, Jesus Manuel Rivera Esteban, Elisa Merino Peña
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI22/00880
Duration: 01/01/2023 - 31/12/2025

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Malalties hepàtiques, Maria Buti Ferret, Montserrat Gomez Perez, Torrens Buscató, Maria Margarita, Judit Vico Romero, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, Jesus Manuel Rivera Esteban, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano, Cesar Jimenez Hernandez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Screening for liver fibrosis - population-based study across European countries

IP: Juan Manuel Pericàs Pulido
Collaborators: Joan Genescà Ferrer, Maria Francesca Cortese, Jesus Manuel Rivera Esteban, Laura Puente Ramo, Juan Bañares Sanchez
Funding agency: EUROPEAN COMMISSION
Funding: 172385.95
Reference: LIVERSCREEN_H2020SC1BHC2019
Duration: 01/01/2020 - 30/06/2025

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Diana Francesco

Diana Francesco

Read more
Nuria Martínez Royuela

Nuria Martínez Royuela

Administration and Management
Clinical Neuroimmunology
Read more
Mariona Colom Saborit

Mariona Colom Saborit

Research technician
Rheumatology
Read more
Carolina Gimeno Garcia

Carolina Gimeno Garcia

Research technician
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.